Beyond acid inhibition: new therapies and innovative approaches
Abstract
Peptic ulcer disease is no longer viewed as an exclusively "acid-dependent" condition.Although proton pump inhibitors (PPI) dominated therapy for decades, their limitations (genetic variability, rebound acid hypersecretion, and bacterial resistance) have driven a paradigm shift.Current management is now more comprehensive, combining acid control with mucosal restoration and effective Helicobacter pylori eradication.Potassium-competitive acid blockers (P-CAB), such as vonoprazan and tegoprazan, provide faster, more potent, and more predictable acid suppression than PPIs, achieving higher healing and eradication rates, even in resistant strains.In parallel, modern H. pylori regimens, including dual and quadruple P-CAB-based therapies, reach eradication rates close to 95%.Mucosal protective agents (rebamipide, sucralfate, misoprostol) are being re-emphasized, along with emerging regenerative therapies that promote epithelial repair.In addition, the gastric microbiota has gained recognition as a key factor, with probiotics and symbiotics improving tolerability, adherence, and clinical outcomes.The future points toward personalized medicine: pharmacogenomics, artificial intelligence, and regenerative strategies will enable more precise, effective, and sustainable treatments.
Read the paper
Related studies
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
- Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.